In a patient taking ezetimibe 10 mg daily who develops new‑onset leg cramps, what is the appropriate evaluation and management?

Ezetimibe and Leg Cramps: Evaluation and Management

Ezetimibe monotherapy is not a recognized cause of leg cramps, and the symptom is likely unrelated to the medication. However, a systematic evaluation is warranted to rule out other causes and determine whether continuation of ezetimibe is appropriate.

Initial Assessment

When a patient on ezetimibe 10 mg daily develops new-onset leg cramps, focus your evaluation on:

• Medication review: Verify the patient is taking ezetimibe alone (not in combination with a statin or bempedoic acid)
• Electrolyte abnormalities: Check serum potassium, magnesium, and calcium levels
• Volume status: Assess for dehydration
• Renal function: Obtain serum creatinine and eGFR
• Concurrent medications: Review for diuretics, beta-agonists, or other drugs that may cause cramps
• Metabolic causes: Consider thyroid function tests if clinically indicated

Evidence Supporting Ezetimibe's Safety Profile

The FDA-approved prescribing information for ezetimibe lists common adverse reactions (≥2% incidence) as upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza 1. Notably, muscle cramps are not listed as a recognized adverse effect of ezetimibe monotherapy.

The 2022 ACC Expert Consensus on nonstatin therapies confirms that ezetimibe monotherapy is associated with upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in extremities—but does not include muscle cramps or leg cramps 2. When combined with statins, the adverse effect profile includes nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, and diarrhea 2.

Critical distinction: While ezetimibe can cause myalgia (muscle pain) when combined with statins, this is different from muscle cramps. The 2025 ACC/AHA ACS Guidelines emphasize that ezetimibe is "well-tolerated without any clear imbalances in adverse events compared with placebo" 3.

Muscle-Related Effects: What the Evidence Shows

A large safety analysis of 4,558 patients comparing ezetimibe/simvastatin combination to simvastatin alone found that ezetimibe does not enhance or aggravate muscle effects 4. The incidence of musculoskeletal adverse events, myalgia, and creatine kinase elevations was no higher with ezetimibe combination therapy than with statin monotherapy 4.

In a study of 286 CKD patients, the combination of statin plus ezetimibe actually had fewer adverse effects (including muscle complaints) compared to statin uptitration: 9/145 (6.2%) in the combination group versus 24/141 (17%) in the statin uptitration group 5.

Management Algorithm

Step 1: Continue Ezetimibe

Do not discontinue ezetimibe based on leg cramps alone. The symptom is almost certainly unrelated to the medication.

Step 2: Address Likely Causes

• Correct any identified electrolyte abnormalities (particularly magnesium and potassium)
• Ensure adequate hydration
• Recommend nonpharmacologic interventions that patients find helpful: stretching, massage, walking 6

Step 3: Symptomatic Treatment if Needed

If cramps are severe and persistent after addressing reversible causes:

• Consider magnesium supplementation (if levels are low-normal)
• Advise stretching exercises before bedtime
• Avoid over-the-counter analgesics as routine treatment, as they carry their own risks 6

Step 4: Monitor and Reassure

• Reassess in 2-4 weeks
• If cramps persist despite correction of reversible factors, consider alternative diagnoses (peripheral vascular disease, neuropathy, spinal stenosis)

Special Considerations

If the patient is actually taking ezetimibe combined with bempedoic acid (not ezetimibe alone), muscle spasms are a recognized adverse effect of bempedoic acid 2. In this scenario, the bempedoic acid component—not ezetimibe—would be the likely culprit.

Common pitfall: Patients may attribute any new symptom to their most recently started medication. Leg cramps are extremely common in the general population 6, and temporal association does not establish causation. The robust safety data for ezetimibe monotherapy strongly argues against a causal relationship.

Bottom line: Maintain ezetimibe therapy while systematically evaluating and treating the actual cause of leg cramps, which is almost certainly unrelated to the medication.